RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Prostate Cancer Channel

subscribe to Prostate Cancer newsletter
Latest Research : Cancer : Prostate Cancer

   EMAIL   |   PRINT
Innovative planning techniques to help men with prostate cancer avoid erectile dysfunction after radiation treatment.

Jan 7, 2005 - 12:59:00 AM

 
[RxPG] Researchers at the University of Michigan Comprehensive Cancer Center are using innovative planning techniques to help men with prostate cancer avoid erectile dysfunction after radiation treatment.

By using MRI scans in addition to CT scans, radiation oncologists can identify the blood vessels that control erectile function and plan treatment to target the prostate more precisely, sparing those nearby vessels. Results from an initial study with 25 patients appear in the January issue of the International Journal of Radiation Oncology Biology Physics.

Some 230,000 men were diagnosed with prostate cancer in 2004. While it's more common in older men, a growing number of men are being diagnosed in their 50s.

"As we treat younger men, erectile function is an important concern. We're often treating men in their 50s, and this is a very important issue for them. Most of the men I see are going to be cured. Once you start curing cancers at an extremely high rate, then the focus moves to quality of life," says Patrick W. McLaughlin, M.D., clinical professor of Radiation Oncology at the University of Michigan Medical School and director of Providence Hospital Radiation Oncology, with cancer centers in Southfield and Novi, both affiliated with the U-M Comprehensive Cancer Center.

Treatment for prostate cancer can involve surgery to remove the prostate or radiation therapy. During surgery, the nerves that control erectile function may be severed – which has led to new surgical techniques to avoid cutting those nerves.

But doctors are less sure what causes erectile dysfunction after radiation therapy. Erectile dysfunction among men without prostate cancer is most commonly caused by a problem in the blood vessels, and doctors do know that radiation causes obstruction of the vessels that fall within the treatment area. Using that as a starting point, the U-M team began investigating radiation-related erectile dysfunction as a blood vessel problem.

Typically, radiation oncologists rely on a CT scan to identify the prostate and plan treatment. But because of limitations in the CT scan, the images do not show the bottom of the prostate. Doctors instead estimate where the prostate ends, based on average distance from identifiable structures. The U-M study, using MRI in addition to CT scans to get a better picture of the whole prostate, found the distance between the prostate and the penile bulb ranged from 0.5 cm to 2.0 cm.

"We condemned one of the common tricks people try to use. By assuming an average distance of 1.5 cm between the prostate and the penile bulb, either you're going to treat way more than you need to or you're going to miss the prostate," McLaughlin says.

By taking the additional imaging, the U-M team was able to plan treatment to include the entire prostate but avoid the critical blood vessels below. Preliminary results suggest that avoiding the vessels prevents erectile dysfunction.

"Because we can't see any detail of this area on CT scans, we just assume if we treat below the prostate it's no big deal. But it is a big deal. There is no cancer below the prostate, but there are critical structures related to erectile function as well as urine sphincter function. Treating below the prostate may result in needless problems," McLaughlin says. "I don't have much doubt from what I've seen that this approach is likely to have huge impact."

About one in two men who undergoes radiation therapy for prostate cancer is unable to have sex five years later unless Viagra or similar medications are used.

In addition, the vessels involved in erectile function also play a role in bowel and bladder control. The researchers suspect avoiding radiation to these areas will improve other quality of life issues, such as urinary leakage and bowel problems.

In addition to McLaughlin, U-M study authors were Vrinda Narayana, Ph.D., adjunct clinical assistant professor of Radiation Oncology; Amichay Meriowitz, M.D., Sara Troyer, Peter Roberson, Ph.D., Howard Sandler, M.D., Lon Marsh, Theodore Lawrence, M.D., and Marc Kessler, Ph.D. Narayana is also affiliated with the Providence Cancer Center. Roger Gonda Jr., M.D., from Providence Hospital's Department of Radiology is also a study author.



Publication: Reference: International Journal of Radiation Oncology Biology Physics, Vol. 61, issue 1, pp 20-31.
On the web: University of Michigan  

Advertise in this space for $10 per month. Contact us today.


Related Prostate Cancer News
Abiraterone has been approved for men with metastatic prostate cancer that is no longer responsive to therapy with hormones and docetaxel
Virus associated with prostate cancer tumors and chronic fatigue syndrome unlikely to be the cause
Acupuncture helps with side effects of prostate cancer treatment
Surgery superior to drug therapy for symptoms of benign prostatic hypertrophy
Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer
Inhibition of TNF-receptor associated protein-1possible treatment for prostatic cancer
Oncologists present test to predict survival in castration-resistant prostate cancer patients
PSA levels appear to be predictive of three year prostate cancer risk in African-American men
Survey on PSA screening in young men
New, noninvasive prostate cancer test beats PSA in detecting prostate cancer

Subscribe to Prostate Cancer Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)